News

Deal Announcements

aTyr Pharma Adds Series E Round

Thursday, April 2, 2015 5:33:00 AM PDT | VentureDeal
   San Diego, California  --  Pharmaceutical technology company aTyr Pharma has secured $76 million in its fifth round of institutional venture capital investment.

aTyr is developing proprietary methods for discovering Physiocrines.

Physiocrines are extracellular proteins that are derived from the tRNA synthetase family of enzymes.

Sofinnova Ventures and an unnamed investor led the round, which included a large syndicate of institutional investors.

The company said it will use the proceeds to further develop its pipeline and advance its lead program through clinical trials.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1